Join the community - networking, discussion and more. Open to all.
More informationCould you write an interesting article for the RQA community?
More informationReleased January 2025
Final guidance released
An at-a-glance summary of news from around the agency
11th and 12th February 2025
Blog post by Essam Kerwash The International Council for Harmonisation (ICH) M15 Model informed Drug development (MIDD) Guideline has reached Step 2b and is available for public consultation. As a clinical pharmacology assessor at the UK Medicines and Healthcare products Regulatory Agency (MHRA), I was involved with the development of this guidance.
A suite of guidance has been published by the Medicines and Healthcare products Regulatory Agency (MHRA).
Out now!
The ICH E6(R3) Guideline reached Step 4 of the ICH process on 6 January 2025.
The Medicines and Healthcare products Regulatory Agency (MHRA) published its first Patient Involvement Strategy in October 2021, covering the period to 2025.
A programme to help facilitate robust decision-making across the entire lifecycle of products, benefitting both regulatory and Health Technology Assessment (HTA) evaluations relevant to the UK.